Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064732 | 0.83 | RPS6KA3 (0.33) | RPS6KA3CCNCCDK8MAPTGSK3B | |
| SCHEMBL3810939 | 0.83 | RPS6KA3 (0.42) | RPS6KA3CCNCCDK8MAPTGSK3B | |
| SCHEMBL31250363 | 0.83 | RPS6KA3 (0.42) | RPS6KA3CCNCCDK8MAPTGSK3B | |
| SCHEMBL27850827 | 0.79 | CCNC (0.40) | RPS6KA3CCNCCDK8MAPTGSK3B | |
| SCHEMBL20524310 | 0.79 | LMNA (0.35) | RPS6KA3CCNCCDK8MAPTAXL | |
| SCHEMBL2892375 | 0.77 | GAA (0.41) | RPS6KA3CCNCCDK8MAPTGSK3B | |
| SCHEMBL783489 | 0.76 | CA12 (0.33) | RPS6KA3CCNCCDK8MAPTAXL | |
| SCHEMBL31407218 | 0.76 | CYP3A4 (0.38) | RPS6KA3CCNCCDK8MAPTAXL | |
| SCHEMBL26272345 | 0.76 | TP53 (0.34) | RPS6KA3CCNCCDK8MAPTAXL | |
| SCHEMBL31407208 | 0.76 | CYP3A4 (0.38) | RPS6KA3CCNCCDK8MAPTAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-3806958-B1 | 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-07 | — | — | EP | disclosed |
| EP-3807261-B1 | PYRIDINYL PYRAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-13 | — | — | EP | disclosed |
| EP-3807261-B1 | PYRIDINYL PYRAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-13 | — | — | EP | disclosed |
| US-11034658-B2 | Pyridinyl pyrazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-15 | — | — | US | disclosed |
| US-11034658-B2 | Pyridinyl pyrazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-15 | — | — | US | disclosed |
| EP-3806958-A1 | 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | disclosed |
| EP-3807261-A1 | PYRIDINYL PYRAZOLES AS MODULATORS OF RORYT | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | disclosed |
| US-10975057-B2 | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-13 | — | — | US | disclosed |
| CN-102712589-A | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2012-10-03 | — | — | CN | disclosed |
| EP-2501678-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| CN-102459247-A | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2012-05-16 | — | — | CN | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034658-B2 | Pyridinyl pyrazoles as modulators of RORγT | RORC, RORB, RORA | RPS6KA3 615/4885CCNC 3146/4885CDK8 1740/4885 |
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | RPS6KA3 2215/4885CCNC 2316/4885CDK8 3094/4885 |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | RPS6KA3 2328/4885CCNC 4180/4885CDK8 2205/4885 |
| US-10975057-B2 | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT | RORC, RORA, RORB | RPS6KA3 317/4885CCNC 2862/4885CDK8 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.